|Page (1) of 1 - 04/23/18||email article||print page|
(April 23, 2018)
DGAP-News: MOLOGEN AG / Key word(s): Miscellaneous
PRESS RELEASE N 10 / 2018 of 23/04/2018
MOLOGEN AG: Announcement of the new dates for the publication of the Annual Financial Statements 2017 and the 2018 Annual General Meeting
Berlin, 23 April 2018 - The biopharmaceutical company MOLOGEN AG announced today the new dates for the publication of the Annual Financial Statements 2017 on 25 April 2018 and the holding of the Annual General Meeting on 8 June 2018.
The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead product candidate lefitolimod and the next-generation molecule family EnanDIM(R).
The immunotherapeutic agent lefitolimod is the company's lead product candidate and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in small cell lung cancer have been announced in April 2017, and the final analysis in the first quarter 2018 confirmed the data. Furthermore, data from the extension phase of the TEACH study in HIV have also been published in 2017. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200, SIN 663720) are listed in the Prime Standard of the German Stock Exchange.
Note about risk for future predictions
|Phone:||030 / 841788-0|
|Fax:||030 / 841788-50|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter